Strategies for the long-term treatment of schizophrenia: Real-world lessons from the CATIE trial

Journal of Clinical Psychiatry

Volumn 68, Issue SUPPL. 1, 2007, Pages 28-33

  Meyer, Jonathan M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; BILE ACID SEQUESTRANT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUROLEPTIC AGENT; NICOTINIC ACID; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

BODY MASS; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LIFESTYLE; LONG TERM CARE; MENTAL HEALTH; METABOLIC DISORDER; METABOLIC SYNDROME X; MORTALITY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOSOCIAL REHABILITATION; REVIEW; SCHIZOPHRENIA; SCREENING; SEXUAL DYSFUNCTION; SIDE EFFECT; SUBSTANCE ABUSE; TREATMENT OUTCOME; VOCATIONAL REHABILITATION; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; CLINICAL TRIALS; HUMANS; LIFE STYLE; METABOLIC SYNDROME X; PATIENT COMPLIANCE; PATIENT EDUCATION; RISK FACTORS; SCHIZOPHRENIA;

EID: 33846980155     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Harvey PD, Jacobsen H, Mancini D, et al. Clinical, cognitive and functional characteristics of long-stay patients with schizophrenia: a comparison of VA and state hospital patients. Schizophr Res 2000;43:3-9
2. Meyer JM, Nasrallah HA, McEvoy JP, et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res 2005;80:9-18
3. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115-1121
4. Regier D, Farmer M, Rae D, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990;264:2511-2518
5. Kavanagh DJ, McGrath JJ, Jenner L. Substance use in psychotic disorders: results from the Australian Survey of Mental Health and Wellbeing. Acta Psychiatr Scand 2000;102(suppl):404-405
6. Krystal JH, D'Souza DC, Madonick S, et al. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophr Res 1999;35(suppl):S35-S49
7. Kavanagh DJ, McGrath J, Saunders JB, et al. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 2002;62:743-755
8. Adler LE, Hoffer LD, Wiser A, et al. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993;150:1856-1861
9. Levin ED, Wilson W, Rose JE, et al. Nicotine-haloperidol interactions and cognitive performance in schizophrenia. Neuropsychopharmacology 1996;15:429-436
10. Kumari V, Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev 2005;29:1021-1034
11. Bellack AS. Skills training for people with severe mental illness. Psychiatr Rehabil J 2004;27:375-391
12. Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behavior. New York, NY: Guilford Press; 1991
13. Drake R, Mercer-McFadden C, Mueser K, et al. Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophr Bull 1998;24:589-608
14. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res 2000;45:21-28
15. Meyer JM. Cardiovascular illness and hyperlipidemia in patients with schizophrenia. In: Meyer JM, Nasrallah H, eds. Medical Illness and Schizophrenia. Washington, DC: American Psychiatric Press, Inc.; 2003:59-89
16. Jones DR, Macias C, Barreira PJ, et al. Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatr Serv 2004;55:1250-1257
17. Dickey B, Normand SL, Weiss R, et al. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv 2002;53:861-867
18. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE Study and matched controls. Schizophr Res 2005;80:45-53
19. Evins AE, Mays V, Cather C, et al. A placebo-controlled trial of sustained release bupropion added to cognitive behavioral group therapy for smoking cessation in schizophrenia. Nicotine Tob Res 2001;3:397-403
20. George TP, Vessicchio JC, Termine A, et al. A placebo-controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002;52:53-61
21. McEvoy JP, Meyer JM, Nasrallah HA, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32
22. Saari KM, Lindeman SM, Viilo KM, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 2005;66:559-563
23. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-1349
24. Meyer JM. Prevalence of hepatitis A, hepatitis B and HIV among hepatitis C-seropositive state hospital patients: results from Oregon State Hospital. J Clin Psychiatry 2003;64:540-545
25. Rosenberg SD, Goodman LA, Osher FC, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Pub Health 2001;91:31-37
26. Bellack AS, Bennett ME, Gearon JS, et al. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry 2006;63:426-432
27. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004;72:41-51
28. Silverstein SM, Wilkniss SM. At issue: the future of cognitive rehabilitation of schizophrenia. Schizophr Bull 2004;30:679-692
29. Twamley EW, Jeste DV, Lehman AF. Vocational rehabilitation in schizophrenia and other psychotic disorders: a literature review and meta-analysis of randomized controlled trials. J Nerv Ment Dis 2003;191:515-523
30. Twamley EW, Padin DS, Bayne KS, et al. Work rehabilitation for middle-aged and older people with schizophrenia: a comparison of 3 approaches. J Nerv Ment Dis 2005;193:596-601
31. Magliano L, Fiorillo A, Fadden G, et al. Effectiveness of a psychoeducational intervention for families of patients with schizophrenia: preliminary results of a study funded by the European Commission. World Psychiatry 2005;4:45-49
32. Pharoah F, Mari J, Rathbone J, et al. Family intervention for schizophrenia. Cochrane Database Syst Rev 2006;4:CD000088
33. Dolder CR, Lacro JP, Leckband S, et al. Interventions to improve antipsychotic medication adherence: review of recent literature. J Clin Psychopharmacol 2003;23:389-399
34. Weiden PJ, Mackell JA, McDonnell D. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004;66:51-57
35. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
36. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-622
37. Dixon L, Postrado L, Delahanty J, et al. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis 1999;187:496-502
38. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006;86:15-22
39. Straker D, Correll CU, Kramer-Ginsberg E, et al. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 2005;162:1217-1221
40. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004;24:S7-S14
41. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
42. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19(suppl 1):1-93
43. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive Summary. Bethesda, Md: National Heart, Lung, and Blood Institute; May 2001. NIH Publication No. 01-3670
44. Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002;25:2165-2171
45. Loh C, Meyer JM, Leckband SG. A comprehensive review of behavioral interventions for weight management in schizophrenia. Ann Clin Psychiatry 2006;18:23-31
46. Weiden PJ, Daniel DG, Simpson G, et al. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003;23:595-600
47. Weiden PJ, Loebel A, Yang R, et al. Course of weight & metabolic benefits 1 year after switching to ziprasidone [abstract]. Presented at the 157th annual meeting of the American Psychiatric Association; May 5, 2004; New York, NY
48. Meyer JM, Pandina G, Bossie CA, et al. Impact of an open-label switch from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder. Clin Ther 2005;27:1930-1941
49. Remington G, Chue P, Stip E, et al. The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res 2005;76:267-272